GlassScriptPhysician profile
Kimberley Augustin
NPI 1447789490
$6,224.35
in general payments reported to CMS, 2019-2025
25 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,023 · 2022: $695 · 2023: $1,529 · 2024: $2,051 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,505.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,387.33 | 2021-2025 | Ingrezza |
| Abbvie INC. | $966.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $622.69 | 2021-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $528.75 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $453.15 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $388.70 | 2023-2025 | Epclusa |
| Pfizer INC. | $321.20 | 2021-2025 | |
| Viiv Healthcare Company | $269.30 | 2021-2025 | Apretude, Dovato |
| Exact Sciences Corporation | $220.66 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $215.06 | 2021-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $163.10 | 2022-2024 | |
| Glaxosmithkline, LLC. | $155.83 | 2021-2024 | Bexsero, Shingrix, Arexvy |
| Renalytix Ai, INC. | $106.30 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Teva Pharmaceuticals USA, INC. | $91.81 | 2021-2022 | |
| Shield Therapeutics INC | $60.87 | 2023-2024 | Accrufer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $58.04 | 2021 | |
| Philips North America LLC | $40.97 | 2024 | (Ck7) Extended Holter |
| Phadia US INC. | $29.16 | 2024 | Immunocap |
| Global Blood Therapeutics, INC. | $22.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.75 | 2022 | |
| Eisai INC. | $21.45 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.95 | 2021 | |
| Indivior INC. | $19.62 | 2021 | |
| Amgen INC. | $18.26 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Augustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.